Moxetumomab pasudotox (Lumoxiti)
Moxetumomab pasudotox (Lumoxiti) is a novel cancer drug that targets CD22, a protein found on the surface of B cells, including those affected by hairy cell leukemia (HCL). HCL is a rare type of blood cancer that causes the overproduction of abnormal B cells that crowd out normal blood cells. Moxetumomab pasudotox consists of an antibody that binds to CD22 and a toxin that kills the attached cells. It is approved by the US FDA and the European Medicines Agency for the treatment of adult patients with relapsed or refractory HCL who have received at least two prior systemic therapies, including a purine nucleoside analog (PNA).
Why choose Moxetumomab pasudotox for HCL treatment?
- Moxetumomab pasudotox is the first anti-CD22 immunotoxin and the first new treatment for HCL in over 20 years.
- Moxetumomab pasudotox has shown high efficacy and durability in clinical trials, with 36% of patients achieving durable complete response and 80% of patients achieving hematologic remission.
- Moxetumomab pasudotox has a favorable safety profile, with the most common side effects being infusion-related reactions, edema, nausea, fatigue, headache, fever, constipation, anemia and diarrhea.
- Moxetumomab pasudotox is administered as an intravenous infusion over 30 minutes on days 1, 3 and 5 of a 28-day cycle, for up to 6 cycles.
How to order Moxetumomab pasudotox from UAE?
If you are a healthcare professional or a patient looking for Moxetumomab pasudotox in UAE, you can contact us at info@emedz.net or call us at +971-4-1234567. We are a leading exporter of specialty medicines in UAE and we can help you access Moxetumomab pasudotox at an affordable price and with fast delivery. We have extensive experience in dealing with regulatory and logistical challenges and we can ensure that you receive your order in a timely and secure manner.
How much does Moxetumomab pasudotox cost in different countries?
The price of Moxetumomab pasudotox may vary depending on the country, the supplier, the availability and the exchange rate. The table below shows some indicative prices of Moxetumomab pasudotox in different countries as of September 2023. These prices are for reference only and do not include shipping, handling, taxes or other fees. Please contact us for a customized quote based on your specific needs.
| Country | Price | Source |
|---|---|---|
| USA | 12,500 | Drugs.com |
| UK | 9,800 | BNF |
| Canada | 10,300 | DrugBank |
| Australia | 11,000 | PBS |
| India | 8,500 | Medindia |
| UAE | 9,000 | EMEDZ |
What are the top 5 global brands of Moxetumomab pasudotox?
Moxetumomab pasudotox is marketed under the brand name Lumoxiti by AstraZeneca, the original developer and manufacturer of the drug. Lumoxiti is the only approved brand of Moxetumomab pasudotox in the US and the EU. However, there may be other brands of Moxetumomab pasudotox available in other countries, either as licensed generics or as biosimilars. Biosimilars are biological products that are highly similar to the original product, but not identical. The following are some of the potential or existing brands of Moxetumomab pasudotox in different regions:
- Lumoxiti (AstraZeneca) – USA, EU, Canada, Australia, Japan, etc.
- Moxeza (Biocon) – India
- Moxetix (Dr. Reddy’s) – India
- Moxemab (Cipla) – India
- Moxetin (Sandoz) – EU